Articles tagged with Molecular Imaging
Researchers evaluated two somatostatin receptor PET tracers for breast cancer treatment, found SSTR-positive tumors in many estrogen receptor-positive cases. A new PET tracer showed promise for detecting Staph infections, while an interim PET scan may help track response to PSMA therapy in advanced prostate cancer.
Mary Beth Farrell has been honored with the 2026 SNMMI-TS Lifetime Achievement Award for her decades-long dedication to elevating the nuclear medicine profession. Her leadership in accreditation, research, and education has shaped national standards and driven quality improvement initiatives that continue to impact patient care.
Research on targeted radioactive gold nanoparticles shows promise against aggressive brain tumors. Ultra-high-resolution PET scanners provide detailed views of mouse brains. New imaging tracers target key drivers of prostate cancer growth.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has announced the recipients of five Drs. Jane & Abass Alavi Mars Shot Research Awards, supporting studies on inflammatory bowel disease, artery inflammation, and other conditions.
The Journal of Nuclear Medicine has published several groundbreaking studies on targeted radiotherapy approaches for various types of cancer. Researchers have successfully identified tumors using fibroblast activation protein (FAP)-targeting compounds and explored the potential of PET/MRI scans in detecting endometriosis and recurrent ...
The SNMMI 2026 Annual Meeting showcased significant advancements in precision nuclear medicine, AI, theranostics, and molecular imaging. The meeting featured over 1,500 abstracts, a 25% increase from last year's meeting, and presented new educational sessions alongside networking opportunities.
Heather Jacene, MD, has been named president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), with a focus on strengthening the organization and advancing nuclear medicine. She plans to create new opportunities for members to participate actively in SNMMI and conduct multidisciplinary collaborations.
A new PET imaging approach measures synaptic density in the spinal cord, allowing physicians to monitor disease progression and evaluate treatment effectiveness. This technique detects widespread reductions in synaptic connections across the brain and spinal cord in patients with multiple sclerosis.
Jason Lewis, PhD, FSNMMI, has been elected as SNMMI's vice president-elect. He aims to strengthen education, scientific exchange, and outreach efforts to integrate basic scientists into SNMMI programs. Lewis holds various academic and research positions.
A new end-to-end PET imaging approach for osteosarcoma distinguishes tumor tissue from normal tissue and assesses surgical margins in real-time. The platform enables precise tumor resection, reducing the risk of local recurrence and preserving maximum limb function.
Gary Ulaner, a renowned nuclear medicine expert, has been elected president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). He aims to advance SNMMI's Mars Shot initiative, expand educational activities for professionals, and increase funding for training new radiochemistry and physics specialists.
Researchers have identified RET as a biomarker for neuroendocrine prostate cancer and developed a theranostic pair for PET imaging and radioligand therapy. The approach demonstrates high uptake in tumors and shows promise for treatment, offering an alternative to current PSMA-based imaging.
A newly developed portable point-of-care PET technology provides high-quality results for guiding biopsies, tumor ablations, and other interventional procedures. The bedside device offers real-time visual feedback, making it a cost-effective approach for hospitals to perform procedures in constrained clinical environments.
A new PET radiotracer can effectively image overactive adrenal glands, allowing for a non-invasive approach to diagnose primary aldosteronism. This could enable physicians to tailor treatment plans for patients with this condition.
A new PET tracer targeting carbonic anhydrase IX (CAIX) has demonstrated exceptional sensitivity and high tumor-to-background contrast in detecting clear cell renal cell carcinoma (ccRCC). The tracer successfully identified additional metastatic lesions missed by standard imaging while reducing abdominal background noise.
Dr. Martin G. Pomper has been awarded the 2026 Benedict Cassen Prize for his outstanding contributions to nuclear medicine, particularly in the development of PSMA-targeted agents. His work has led to significant advances in cancer diagnosis and treatment, including the creation of commercial PSMA-targeted PET agents.
A novel PET imaging framework reveals bariatric surgery induces coordinated changes in metabolic function across organs, including fat, liver, pancreas, muscle, and immune-endocrine organs. These findings support the use of whole-body PET/CT as a tool to map organ-level metabolic health.
A new PET radiotracer, 18F-GP1 PET/CT, accurately detects deep vein thrombosis in the legs and reveals lung clot migration. The approach may support faster diagnosis and improve patient care by detecting disease early.
A new type of peptide receptor radionuclide therapy (PRRT) shows promise in treating metastatic neuroendocrine tumors. The novel approach resulted in partial remission in the majority of patients with advanced cases, with manageable safety and encouraging antitumor activity.
Researchers developed a novel PET imaging approach to detect immune-related adverse events in patients receiving immunotherapy. The approach uses CCR2-targeted radiotracer to visualize both tumor progression and cardiac inflammatory responses. Co-treatment with itacitinib improved tumor response while reducing cardiac inflammation.
Dr. Richard E. Carson has made significant contributions to the understanding and application of nuclear medicine, particularly in neuroscience and neuropsychiatric disorders. His work led to the development of diverse tracer kinetic modeling techniques and innovative imaging systems like NeuroEXPLORER.
A study found that a specific pattern of brain metabolism visualized with PET imaging can predict which patients are most likely to benefit from Alzheimer's disease therapy. Patients with this pattern experienced stabilized cognitive performance, while those with other patterns had significant cognitive decline.
A new SPECT/CT imaging approach can accurately differentiate between inflammation and fibrosis in interstitial lung disease (ILD) patients. Researchers used the molecular imaging agent ⁹⁹ᵐTc-maraciclatide to visualize inflammation, which is crucial for determining treatment decisions.
Johnson aims to protect and advance the scope of practice for nuclear medicine technologists, strengthening the national workforce pipeline through education-driven partnerships with industry. She will also formalize standardized training resources as new technologies are introduced.
Irène Buvat, a pioneering researcher, has received the SNMMI's George Charles de Hevesy Nuclear Pioneer Award for her groundbreaking work in molecular imaging quantification. Her contributions have led to improved diagnosis and treatment of cancer through the development of simulation and radiomics tools.
Researchers developed a new tau PET radiotracer that can accurately detect chronic traumatic encephalopathy (CTE) in living patients. The tracer's ability to bind to tau pathology was confirmed in post-mortem CTE tissue, and preliminary results suggest it could provide an early diagnostic biomarker for the disease.
PSMA PET scans have been shown to detect bone metastases that conventional imaging misses, resulting in faster disease progression and worse overall survival. Patients with these undetected lesions are at a higher risk of progressing to treatment-resistant cancer and dying sooner.
Shannon Youngblood has been elected as the new president of the SNMMI Technologist Section. She will focus on amplifying visibility through advocacy, building a more inclusive workforce through educational opportunities, and streamlining professional development to stay current with advancements in theranostics and cardiac PET-CT.
The Society of Nuclear Medicine and Molecular Imaging recognized six new Fellows for their exceptional contributions to the field. The SNMMI Fellowship honors members who have demonstrated excellence in scientific discovery, educational efforts, or clinical practice.
Vasken Dilsizian, MD, has received the Minoshima-Pappas Transformational Leadership Award for his vision and leadership in advancing nuclear medicine and molecular imaging. He has made significant contributions to the field of cardiovascular diseases through his innovative scientific work.
A new machine-learning model uses pre-therapy PET/CT scans to estimate radiation dose to tumors and healthy organs, improving patient selection and reducing toxicity risk. The study's findings suggest a promising ability to predict post-therapy dosimetry, which may optimize treatment plans for individual patients.
Researchers have made significant breakthroughs in nuclear medicine, with studies revealing uneven radiation doses in tiny kidney structures, improving survival rates for prostate cancer patients through targeted radiation therapy, and developing a new PET imaging approach to detect abdominal cancer spread. These advancements aim to im...
Recent research published in The Journal of Nuclear Medicine has made significant advancements in brain imaging and cancer treatment. A new wearable brain imaging system, SmartBrain, enables real-time imaging beyond the lab, capturing high-resolution images of brain activity without requiring patients to remain still.
A new pretargeted radioimmunotherapy technique has been shown to be effective and safe in eradicating tumors from a preclinical colorectal cancer model. The multi-step theranostic approach delivers alpha-emitting radiation directly to tumors while limiting exposure to healthy tissues.
Scientists successfully built the smallest X-ray interferometer to measure how X-rays interact with atomic nuclei. This breakthrough technology enables precise measurement of X-ray refraction and provides new avenues for research.
Researchers have made significant breakthroughs in prostate cancer treatment with new imaging techniques and targeted therapies, including a PSMA-targeting antibody and a CD44v6-targeting radiotherapy. These advancements aim to improve patient outcomes by tailoring diagnosis and treatment to individual needs.
A new PET biomarker outperforms established risk scores in predicting survival for large B-cell lymphoma patients. Metabolic tumor volume, derived from PET imaging, was found to be an important predictor of progression-free survival.
Salk scientists and collaborators advance visualization technology using visible-spectrum antigen-stabilizable fluorescent nanobodies (VIS-Fbs), reducing background fluorescence by up to a hundredfold. The new probe enables high spatial and temporal precision, allowing for real-time tracking of dynamic changes in living models.
The SNMMI 2026 Annual Meeting will showcase the latest scientific developments driving advances in nuclear medicine, including earlier diagnosis, personalized treatment, and improved disease management for various conditions. The meeting will feature over 150 scientific sessions, satellite symposia, and a cutting-edge exhibit hall.
Researchers developed a new chelator to improve cancer imaging and therapy. Additionally, analyzing brain glucose uptake in patients with non–small cell lung cancer may help predict prognosis. A targeted PET imaging agent is also being developed to detect liver cancer more effectively.
Researchers have developed new PET tracers that can track synaptic density in epilepsy and monitor tau buildup in Alzheimer's disease. A novel PET tracer also maps cellular energy use across the body, enabling faster imaging approaches for studying mitochondrial function.
Recent studies published in The Journal of Nuclear Medicine have made significant advancements in the field. Researchers have developed a new tracer to detect active collagen turnover following myocardial infarction and evaluated folate-based radioconjugates for ovarian cancer imaging. Additionally, targeted radiotherapy shows promise ...
Bidkar aims to develop a novel CD46-targeted radiotheranostic platform to treat metastatic castration-resistant prostate cancer. His proposal focuses on overcoming tumor heterogeneity and improving treatment outcomes.
Kiran Solingapuram Sai's research aims to detect microtubule dysfunction early in Alzheimer's disease using a first-in-class PET radiotracer. The study will establish a reproducible imaging framework for this target.
Dr. Chun Li has been awarded the SNMMI Mars Shot Research Fund Award to investigate the PET radiotracer 64Cu-DbCD11b for detecting vulnerable atherosclerotic plaques. The study aims to assess the non-invasive assessment of vulnerable plaques and aid in patient risk identification and treatment.
Dr. David H. Ballard, MD, has been awarded a $100,000 grant from the SNMMI Mars Shot Research Fund to develop novel PET/MR imaging techniques for metabolic activity and inflammation in Crohn's disease. The study aims to improve biologically informed decision-making and guide treatment decisions.
Researchers Ansel Hillmer and Eric Webb have received the $100,000 Drs. Jane & Abass Alavi Mars Shot Research Award to advance imaging research in infection and inflammation for Alzheimer's disease. They aim to develop a PET radiotracer targeting CSF1R to diagnose and monitor brain inflammation.
Dr. Carolyn J. Anderson has been awarded a $100,000 grant from the SNMMI Mars Shot Research Fund to develop a PET radiotracer for imaging vaso-occlusive crisis in sickle cell disease. The award will support the production and validation of an easy-to-produce and high-yielding PET radiotracer, 18F-LLP2A, for rapid translation to patients.
The study investigated the link between heart attack-induced inflammation and cognitive decline, as well as the potential of PET-based metabolic tumor volume to predict CAR T-cell therapy outcomes. Additionally, researchers combined advanced imaging with genetic profiling to explore hidden metabolic patterns in recurrent brain cancer.
Researchers Haj-Mirzaian and Heidari aim to develop non-invasive imaging biomarker <sup> 18 </sup> F-NaF PET/CT for early calciphylaxis diagnosis in dialysis-dependent patients. This could lead to timely interventions, reduced mortality, and improved patient outcomes.
Researchers have developed new imaging techniques to detect hidden infections, inflammatory diseases, and cancers, while also evaluating the effectiveness of AI-powered tumor measurement and targeted radiotherapy for advanced solid tumors.
Researchers have developed a new PSMA-targeted PET tracer that shows promise in early human studies, providing strong tumor uptake and favorable radiation dosimetry. Additionally, advanced dynamic PET imaging has been used to track heart amyloid buildup more precisely, detecting significant reductions after six months of tafamidis ther...
A new targeted PET/CT tracer can detect treatment response in rheumatoid arthritis patients as little as four weeks after treatment initiation. The imaging technique uses macrophages, a type of white blood cell, as a biomarker for disease activity, potentially allowing non-responders to pursue more effective therapies.
A novel quantitative imaging approach using PET and MRI can identify limbic-predominant age-related TDP-43 encephalopathy (LATE), a distinct neurodegenerative disorder resembling Alzheimer's disease. This framework may guide targeted diagnostic work-up and personalized care for dementia patients.
Researchers have made significant advancements in nuclear medicine by developing a new reporting framework for PET/CT scans, using targeted radiation therapy to treat sarcoma, and investigating how genetic mutations affect prostate cancer treatment outcomes. These studies aim to improve diagnosis and treatment for various cancers.
Scientists have created a way to hear a single molecule 'sing' using infrared-integrated STM. This technique combines infrared excitation with scanning tunneling microscopy, allowing for the detection of individual molecular vibrations.
Researchers are testing new targeted radiation approaches for early colorectal cancer, HER2-positive breast cancer, and advanced prostate cancer. Imaging tools track treatment movement and help evaluate dosing and safety.
Ken Herrmann will lead the journal for five years, focusing on global engagement and impact. He succeeds Johannes Czernin, who guided JNM through significant growth and expansion.